SCHEMBL10212480

SCHEMBL10212480

COC(=O)c1cccc2nc(-c3ccc(-c4ccccc4)cc3)[nH]c12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
ALDH1A1 P00352 2/20 0.55
HPGD P15428 2/20 0.55
LMNA P02545 1/20 0.55
PKM P14618 1/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
TNKS O95271 2/20 0.55
PKN1 Q16512 1/20 0.49
PKN2 Q16513 1/20 0.49
ERCC1 P07992 1/20 0.49
FEN1 P39748 1/20 0.49
ERCC4 Q92889 1/20 0.49
DHODH Q02127 2/20 0.48
PARP1 P09874 2/20 0.46
RAF1 P04049 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL697780 0.97 KDM4E (0.54) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL29087625 0.90 KDM4E (0.52) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6948237 0.83 TSHR (0.50) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5886053 0.83 TNKS (0.43) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL8832123 0.83 KDM4E (0.49) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL15958955 0.82 PARP1 (0.47) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL696548 0.82 DHODH (0.56) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL8665445 0.80 TNKS (0.40) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL25433684 0.79 SCN1A (0.43) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL505569 0.79 DHODH (0.55) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006454-B2 Dihydroorotate dehydrogenase inhibitors MERCK SERONO S.A. (CH) 2015-04-14 US disclosed
US-9006454-B2 Dihydroorotate dehydrogenase inhibitors MERCK SERONO S.A. (CH) 2015-04-14 US disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 US disclosed
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2012-02-02 US disclosed
WO-2010115736-A2 DIHYDROOROTATE DEHYDROGENASE INHIBITORS MERCK SERONO S.A. (CH) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028959-A1 DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, FH, DPYD KDM4E 806/4885SMN1; SMN2 3315/4885NPC1 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.